MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

SCYNEXIS Inc

Geschlossen

0.9 -4.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.89

Max

0.95

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.6M

-4.4M

Verkäufe

317K

977K

EPS

-0.09

Gewinnspanne

-453.736

Angestellte

28

EBITDA

-1.2M

-4.2M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+373.68% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.5M

38M

Vorheriger Eröffnungskurs

5.16

Vorheriger Schlusskurs

0.9

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

SCYNEXIS Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Apr. 2025, 23:55 UTC

Heiße Aktien

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2. Apr. 2025, 22:50 UTC

Wichtige Markttreiber

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2. Apr. 2025, 21:08 UTC

Ergebnisse

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2. Apr. 2025, 21:00 UTC

Ergebnisse

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2. Apr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2. Apr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Apr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2. Apr. 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2. Apr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Apr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2. Apr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Apr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2. Apr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2. Apr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2. Apr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2. Apr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2. Apr. 2025, 22:43 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2. Apr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2. Apr. 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2. Apr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2. Apr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2. Apr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Apr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2. Apr. 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2. Apr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2. Apr. 2025, 20:53 UTC

Ergebnisse

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2. Apr. 2025, 20:52 UTC

Ergebnisse

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer-Vergleich

Kursveränderung

SCYNEXIS Inc Prognose

Kursziel

By TipRanks

373.68% Vorteil

12-Monats-Prognose

Durchschnitt 4.5 USD  373.68%

Hoch 5 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für SCYNEXIS Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

0.9379 / 1.04Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

No Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.